retinostat
Gene therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01301443)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor CINHIBITOR
VEGFC inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1- Mol. weight
- 323.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707219 ↗
Also known as
- retinostat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03875859 | Phase 2 | Oct 1, 2019 | Stanford University |
| NCT03180528 | Phase 2 | Jul 1, 2017 | Stanford University |
| NCT01678872 | Phase 1 | Aug 1, 2012 | Johns Hopkins University, Oxford BioMedica |
| NCT01301443 | Phase 1 | Feb 1, 2011 | Johns Hopkins University, Oxford BioMedica |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Oxford BioMedica | For profit | 2 | 2 | 1 | 2011 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2017 |
3 organizations
Page 1 / 1